← Back to Clinical Trials
Recruiting NCT06462937

NCT06462937 A Digital Exercise Intervention in Patients With Spondyloarthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06462937
Status Recruiting
Phase
Sponsor Diakonhjemmet Hospital
Condition Spondyloarthritis
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2024-07-01
Primary Completion 2027-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise with supervisionExercise without supervision

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 260 participants in total. It began in 2024-07-01 with a primary completion date of 2027-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This protocol describes a 6-month randomised, controlled exercise trial in patients with axial spondyloarthritis (axSpA) with re-randomization after 3-months. The primary outcome of the trial (disease activity) will be evaluated at 3-months. The exercise programme on trial comprises high intensity interval training (HIIT), muscular strength exercise and aerobic physical activity sessions of specified duration, frequency, and intensity. It also includes brief knowledge videos to empower the patient. The intervention is remotely delivered by the SPARK application with personalised follow-up including monitoring to ensure exercise progression and adherence to exercise intensity. The SPARK application is built on a platform delivered by ABEL Technologies (trademark) and is customised for patients with axSpA.

Eligibility Criteria

Inclusion Criteria: * axSpA diagnosis within the last two years by a rheumatologist according to the ASAS criteria of 2009 * active disease (ASDAS \> 1.3) Exclusion Criteria: * Active uveitis. * CRP \> 30. * Former or current use of bDMARDs. * Pregnancy or planned pregnancy within 6 months from inclusion. * Absolute and relative contradictions to high intensity exercise according to the American College of Sports Medicine (ACSM) * Other serious disease such as cancer. * Patients incapable to follow the protocol or the control set-up with remote monitoring.

Contact & Investigator

Central Contact

Sella A Provan, Professor

✉ SellaProvan@gmail.com

📞 4791582581

Frequently Asked Questions

Who can join the NCT06462937 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spondyloarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06462937 currently recruiting?

Yes, NCT06462937 is actively recruiting participants. Contact the research team at SellaProvan@gmail.com for enrollment information.

Where is the NCT06462937 trial being conducted?

This trial is being conducted at Oslo, Norway.

Who is sponsoring the NCT06462937 clinical trial?

NCT06462937 is sponsored by Diakonhjemmet Hospital. The trial plans to enroll 260 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology